The startup specializes in automated chemoproteomic drug discovery, utilizing high-throughput screening and mass spectrometry to identify potential drug candidates. This approach accelerates the drug development process by efficiently pinpointing molecular interactions and optimizing lead compounds, addressing the lengthy timelines and high costs associated with traditional drug discovery methods.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods are time-consuming and expensive, often involving lengthy timelines and high costs due to inefficient screening processes. Identifying potential drug candidates and optimizing lead compounds can be particularly challenging.
Solution
This startup focuses on automated chemoproteomic drug discovery to accelerate the identification of potential drug candidates. By leveraging high-throughput screening and mass spectrometry, the company efficiently pinpoints molecular interactions. This approach aims to streamline the drug development process, reducing both the time and cost associated with bringing new therapies to market. The technology enables rapid analysis of drug-target interactions, facilitating the optimization of lead compounds for improved efficacy and safety.
Target Audience
The primary audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and development.
Features
- High-throughput screening for rapid identification of drug candidates.
- Mass spectrometry-based analysis for precise molecular interaction mapping.
- Automated workflows to accelerate the drug discovery process.
- Chemoproteomics platform for target identification and validation.